Anterogen.Co., Ltd. Overview
Anterogen is a Seoul-based adult stem-cell company. It was among the first organisations anywhere to bring adipose-derived mesenchymal stem cell (ASC) products to market: Queencell, an autologous stromal-vascular-fraction product approved in 2010, and Cupistem, approved in January 2012 for Crohn's fistula and described as the world's first approved ASC therapy.
Neither domestic product scaled commercially. Queencell's licence was withdrawn in 2026, and Cupistem now generates negligible sales. Current revenue depends mainly on the in-licensed pulmonary arterial hypertension drug Remodulin.
The investment case therefore rests on the company's allogeneic, off-the-shelf, cryopreservable ASC hydrogel sheet platform (ALLO-ASC-Sheet). Japan approved it in April 2026, as "Allostem", for epidermolysis bullosa through licensee Ishin Pharmaceutical. It launched in Japan on 27 July 2026, with Anterogen acting as exclusive manufacturer and supplier.
The second major use of the platform, diabetic foot ulcer, has failed two efficacy readouts. Anterogen is a pre-profitability, low-leverage, equity-funded biotech. Its value now hinges on Japanese Allostem uptake and on ex-Japan expansion.
What the company does
Anterogen researches, develops, manufactures and sells cell-therapy products and orphan drugs based on adult stem cells, chiefly adipose tissue-derived MSCs. It also sells stem-cell-conditioned-media cosmetics and provides stem-cell banking and analytical testing services.
Its commercial and development portfolio has three layers:
-
Approved autologous cell therapies (Korea).
-
Cupistem (autologous ASC injection for Crohn's fistula; MFDS approval January 2012; HIRA reimbursement January 2014).
-
Queencell (autologous adipose SVF for subcutaneous tissue defects; MFDS approval March 2010; licence withdrawn 2026).
-
Adipocell (for depressed scars) is cited in company materials as an earlier product.
-
-
Allogeneic off-the-shelf platform (ALLO-ASC). A hydrogel sheet carrying about 1 million donor-derived ASCs per 5×5 cm sheet. It is cryopreservable for about one year and "ready-made" (no patient-specific culture is needed). Applications:
-
Epidermolysis bullosa (Allostem; approved in Japan in 2026)
-
Diabetic foot ulcer
-
Burns
-
Crohn's disease (injectable)
-
Knee osteoarthritis (ANT-301)
-
-
Non-cell assets.
-
In-licensed Remodulin (treprostinil) injection for pulmonary arterial hypertension, which is currently the main revenue source.
-
A small-molecule herpes zoster antiviral (ANT-501), obtained through the 2022 merger with CSK.
-
Cosmetics: SCM2 and SCM2-Black hair care; Therastem-Derma, Therastem-White Silk and Therastem-White Glutathione skin care; and a "stem cell media program set" cosmetic raw material.
-
Services: stem-cell banking, and sample analysis for clinical studies (identity, purity, potency and adventitious-virus testing).
-
Business and revenue model
| Revenue stream | Model | Status (Oct 2026) | Source |
|---|---|---|---|
| Remodulin injection | In-licensed product distribution in Korea | Described in June 2026 press as effectively the sole meaningful revenue source | Medisobizanews, 15 Jun 2026 |
| Cupistem | Own-product sales; reimbursed (ceiling price KRW 13.49M per treatment, 2014) | Negligible current sales | Biospectator, 2014; Medisobizanews, 2026 |
| Queencell | Own-product sales | Licence withdrawn (June 2026) | Medisobizanews, 15 Jun 2026 |
| Allostem (ALLO-ASC-EB) supply to Ishin | Finished-product supply, plus milestones and a royalty (about 9% of sales, per 2019 press) | First commercial shipment July 2026 | eToday, 2019; Medical Daily, Jul 2026 |
| Licensing income | Upfront and milestone payments from Ishin (EB, DFU and burns licences, Japan/Taiwan) | KRW 3.8bn of upfront and milestones received by c.2016; later milestones NPD | Biospectator, c.2016 |
| Cosmetics | Product sales (B2C/B2B), raw material | Ongoing; revenue NPD | Investing.com profile |
| Services | Stem-cell banking and analytical testing | Ongoing; revenue NPD | Investing.com profile |
Mix by type. Product sales (distribution plus own products) dominate. Licensing is episodic. There is no subscription revenue. A product-by-product revenue split for FY2023–FY2025 is NPD in the sources reviewed.
Value-chain position. For Allostem, Anterogen is a vertically integrated originator and contract manufacturer:
-
It holds the cell banks.
-
It manufactures at its Gasan and Magok GMP sites, both accredited by Japan's PMDA as Foreign Manufacturers in March 2025.
-
It ships finished sheets to Ishin, which holds the Japanese marketing authorisation, carries out commercialisation and holds Taiwan rights.
In Korea, the company sells directly and distributes Remodulin.
Customers and end markets.
-
Hospitals treating rare and severe dermatological diseases: EB in Japan.
-
Gastroenterology and colorectal surgery: Crohn's fistula.
-
Pulmonary hypertension centres: Remodulin.
-
Wound-care settings: DFU, investigational.
-
Orthopaedics: osteoarthritis, investigational.
-
Consumers: cosmetics.
In its IR materials the company describes itself as a bio-venture for "human tissue regeneration" specialising in cell therapies and orphan drugs using adult stem cells. Its founder has framed the strategy as targeting niche rare-disease markets in Japan, the US and Europe that lack competitors, rather than large crowded indications (Biospectator interview, c.2016).
Independent characterisation. Anterogen is best understood as a single-platform, pre-scale rare-disease cell-therapy manufacturer whose domestic legacy products have failed commercially. A thin, low-margin distribution business partially covers fixed costs. The company holds a large equity cushion relative to its liabilities (equity of KRW 87.45bn against total assets of KRW 88.26bn at FY2025), but its operating cash burn is modest and its revenue base is very small.
The April 2026 Japanese approval is the company's first ex-Korea commercial validation. Its economic significance depends on uptake in a patient pool estimated at roughly 500–1,000 in Japan.
Strategy
Stated strategy (themes)
-
Rare-disease niche focus. Target orphan indications with no effective treatment in Japan, the US and Europe, rather than large competitive markets (Lee Sung-gu, Biospectator, c.2016).
-
Off-the-shelf allogeneic platform. Overcome the limits of autologous products (culture lead times of up to four weeks, short shelf life, high cost) with a cryopreserved, mass-producible, exportable ASC sheet (company IR; Biospectator).
-
Partner-led regulatory approval, Anterogen-led manufacturing. Licensees such as Ishin run local development and approval, while Anterogen keeps manufacturing and supply economics plus milestones and royalties (Hankyung, Mar 2025).
-
Japan first, then expansion. Use the Japanese approval as a foothold for two additional countries in Asia and Europe, and for the US through a Phase 2 EB programme (Medical Daily, Jul 2026; Biotimes).
-
Pipeline diversification beyond cell therapy. Add a small-molecule antiviral (ANT-501) through the CSK merger and an osteoarthritis cell therapy (ANT-301) (Medisobizanews, 2026).
Strategic initiatives (last 24 months)
| Initiative | Date | Detail | Source |
|---|---|---|---|
| PMDA Foreign Manufacturer Accreditation | Mar 2025 | Both the Gasan and Magok plants are cleared to supply Japan | Hankyung, Mar 2025 |
| Japanese pre-NDA and NDA (via Ishin) | Apr–Jul 2025 | Pre-NDA meeting (expected 16 Apr 2025); NDA filed 8 Jul 2025 with an expanded label (DEB, JEB, EBS) | Hankyung; Daily Invest |
| PMDA GMP inspection | Dec 2025 | Final pre-approval step; management said all requested supplements had been completed | Hankyung, Dec 2025 |
| Japanese approval and pricing | Apr–Jul 2026 | Approval 3 Apr 2026; insurance price set; launch 27 Jul 2026 | Hankyung; Medical Daily |
| Portfolio rationalisation | Jun 2026 | Queencell licence withdrawn | Medisobizanews |
| ANT-301 progression | 2,026 | Korea Ph1 safety confirmed; US IND under review; Ph2 start targeted within 2026 | Medisobizanews; Medical Daily |
| ANT-501 | 2,026 | Ph1 IND targeted for 2026 | Chickstock IR summary |
| National R&D projects | 2,025 | Government projects on knee OA, stem-cell therapy and 3D culture (12 national R&D projects in total) | THE VC |
ESG commitments and cost programmes
No formal ESG commitments or cost-reduction programme with targets were found. Headcount fell from 43 (FY2022) to 29 (FY2024) without an announced programme.
Medium-term guidance
| Item | Timeline | Source |
|---|---|---|
| Japanese launch | July 2026 (achieved) | IR, Mar 2026 |
| Additional country launches | Two more countries in Asia and Europe | Medical Daily, Jul 2026 |
| ANT-301 Phase 2 | Within 2026 | Medical Daily, Jul 2026 |
| ANT-501 Phase 1 IND | 2,026 | IR, Mar 2026 |
Anterogen does not publish quantitative financial guidance. Operational timelines it has communicated:
Products & Services
Marketed and formerly marketed products
| Product | Type / description | Indication | Key specifications / evidence | Target customer | Approval / launch | Pricing | Status | Source |
|---|---|---|---|---|---|---|---|---|
| Allostem (ALLO-ASC-EB; ALLO-ASC-Sheet) | Allogeneic adipose-derived MSC hydrogel sheet; off-the-shelf; cryopreserved | Dystrophic EB (DEB), junctional EB (JEB), severe EB simplex (Japan label) | Applied weekly in trials; company reports a durable blister-free effect lasting years in some patients; approved as a designated regenerative medical product | Japanese EB treatment centres via Ishin | Japan approval 3 Apr 2026; launch 27 Jul 2026 | Japanese insurance price about JPY 2,955,232 per set (2 vials). The company cites about USD 630,500 per patient per year at 26 vials (see note) | Commercial in Japan; Korea Ph1/2 and US Ph2 ongoing | Hankyung, Apr 2026; IR, 16 Mar 2026 (via Chickstock); Medisobizanews |
| Cupistem injection | Autologous adipose-derived MSC injection | Crohn's fistula | 82% complete healing at week 8; 81% of those sustained at week 96 (company/MFDS summary). Dose 3×10⁷ cells/mL for fistula ≤1 cm; 6×10⁷ cells in 2 mL for 1–2 cm | Gastroenterology / colorectal surgery (Korea) | MFDS Jan 2012; reimbursed Jan 2014 | Ceiling price KRW 13.49M (patient co-pay 10%), 2014 | Marketed; negligible sales (2026) | MFDS; Biospectator; PMC review |
| Queencell | Autologous adipose SVF (MSCs, preadipocytes, endothelial progenitors, pericytes and other cells), minimally manipulated | Subcutaneous adipose tissue defects | 1×10⁶ cells/mL | Aesthetic / reconstructive | MFDS Mar 2010 | NPD | Licence withdrawn, Jun 2026 | MFDS; Medisobizanews |
| Adipocell | Autologous adipose-cell product | Depressed scars | — | Dermatology | Historical (date NV) | NPD | Status NV | AeroLeads company profile |
| Remodulin injection | Treprostinil (in-licensed) | Pulmonary arterial hypertension | — | PAH centres (Korea) | NPD | NPD | Principal revenue source | Investing.com; Medisobizanews |
Note on Allostem economics: The company-cited annual cost of about USD 630,500 per patient (26 vials) cannot be reconciled with the disclosed price of about JPY 2,955,232 per two-vial set. Thirteen sets per year at that price is about JPY 38.4M, which is materially lower in USD terms. The basis of the company figure (FX rate, per-vial versus per-set pricing, or dosing assumption) is not disclosed in the public summary. Investors should rely on the official Japanese price listing.
Development pipeline
| Programme | Modality | Indication | Stage (latest disclosed) | Key data / events | Source |
|---|---|---|---|---|---|
| ALLO-ASC-EB | Allogeneic ASC sheet | DEB/JEB/EBS | Japan approved (Apr 2026); Korea Ph1/2; US Ph2; FDA orphan designation | Japan Ph3 enrolled 6 patients | Medisobizanews, 2026; Edaily, 2022 |
| ALLO-ASC-DFU (KR) | Allogeneic ASC sheet | Diabetic foot ulcer (Wagner 1–2) | Ph3 DFU-301 failed (Jan 2022) | No significant difference in complete wound closure at 12 weeks (mITT). The company attributed this to loss of cell potency during washing of animal-derived serum | Edaily; Dailypharm |
| ALLO-ASC-DFU (KR) | Allogeneic ASC sheet (xeno-free medium) | DFU Wagner 2 | Ph3 DFU-302 (n=104) primary completion 5 Dec 2024; topline result NPD in sources reviewed. 24-month safety follow-up registered | Company still described Korean Ph3 as "in progress" (Jun 2026) | ClinicalTrials.gov; Medisobizanews |
| ALLO-ASC-Sheet (US) | Allogeneic ASC sheet | DFU Wagner 1 (DFU-102, n≈56) | Ph2 failed (topline 31 Jan 2025) | Complete closure at 12 weeks: 45.7% (ALLO-ASC) vs 60% (hydrogel control) | Edaily, Feb 2025 |
| ALLO-ASC-Sheet (US) | Allogeneic ASC sheet | DFU Wagner 2 (DFU-103, n≈64) | Ph2 ongoing; FDA RMAT designation (DFU) | — | Edaily, 2025; IR, 2020 |
| ALLO-ASC-BI | Allogeneic ASC sheet | Deep second-degree burns | Ph2 completed (Jul 2021); no subsequent filing found | — | ClinicalTrials.gov NCT02619851 |
| ALLO-ASC-CD | Allogeneic ASC (injectable) | Crohn's disease | Korea Ph1 | — | Medisobizanews, Jun 2026 |
| ANT-301 | Allogeneic ASC (3D culture referenced in national R&D) | Knee osteoarthritis (Kellgren-Lawrence 3–4) | Korea Ph1 (ANT-301-102) safety confirmed in 6 subjects (Aug 2026); US IND under review; Ph2 planned within 2026 | Company-reported pain reduction of 44% at 24 weeks (low dose) and 63% at 12 months | Kormedi; Chickstock IR summary; Medical Daily |
| ANT-501 | Small-molecule antiviral (from CSK merger) | Herpes zoster | Preclinical; Ph1 IND targeted for 2026 | Company claims about 750× the antiviral potency of acyclovir (preclinical) | Chickstock IR summary; Medisobizanews |
| Herpes simplex programme | Antiviral | Herpes simplex | Early (2023 IR mention) | — | Company IR, May 2023 |
Cosmetics and raw materials
| Product | Category | Description | Source |
|---|---|---|---|
| SCM2 | Hair care | Stem-cell-conditioned-media hair product | Investing.com profile |
| SCM2-Black | Hair care | Line extension | Investing.com profile |
| Therastem-Derma | Skin care | Conditioned-media skin care | Investing.com profile |
| Therastem-White Silk | Skin care | Brightening line | Investing.com profile |
| Therastem-White Glutathione | Skin care | Brightening line | Investing.com profile |
| Stem cell media program set | Cosmetic raw material | B2B ingredient | Investing.com profile |
In 2023 management guided that hair-loss-mitigating functional cosmetics could reach about KRW 10bn in sales (Hankyung, Mar 2023). No subsequent disclosure confirms that level, and total company revenue has not exceeded KRW 8.1bn in any year since.
Services
| Service | Description | Source |
|---|---|---|
| Stem-cell banking | Storage of stem cells | Investing.com profile |
| Analytical testing | Sample analysis for clinical studies; biopharmaceutical tests for identity, purity, potency and adventitious viruses | Investing.com profile |
Financial Narrative
All figures are separate-basis K-IFRS from DART business reports, as compiled by ETF Shopping (updated 12 October 2026). The base unit is KRW 100M (억원), converted to KRW bn and rounded to one decimal. Quarterly figures are from DART quarterly and half-year reports. Figures reflect the latest-filed (amended) reports where the aggregator used them.
Income statement (FY2021–FY2025)
Notes:
-
Diluted EPS is NPD separately. With losses, diluted EPS equals basic.
-
No dividend has been declared in any year shown. The current dividend yield is 0.00% (ETF Shopping).
-
EBITDA and pre-tax income are NPD in the sources for FY2021–FY2025. The aggregator shows EBITDA only for FY2016 (KRW 0.3bn). Investing.com displays a trailing EBITDA of KRW 2.67bn, which is inconsistent with an operating loss of KRW 2.4bn and is treated as unreliable.
-
Revenue CAGR FY2021–FY2025: -1.9% (derived). FY2016–FY2025: +4.8% (derived).
Quarterly trajectory (Q1 2024–Q2 2026)
Notes:
-
The 2024 quarterly YoY growth figures were not provided by the source and are shown as 0 placeholders. Do not chart them.
-
H1 2026 revenue of KRW 4.3bn is up about 23% from KRW 3.5bn in H1 2025 (derived). The H1 2026 operating loss of KRW 1.6bn is flat year on year (derived).
-
The first Allostem shipments (July 2026) fall into Q3 2026, which is due for filing in mid-November 2026.
Source: DART business reports, compiled by ETF Shopping. FY2025 total payroll was KRW 1.1bn.
Sources: financialfilings.com (amended FY2025 annual report, filed 15 May 2026) for total assets, equity and CFO; Craft for cash and equivalents.
With only KRW 1.6bn in cash and equivalents against total assets of KRW 88.26bn, the bulk is presumably short-term financial instruments, the Magok R&D centre and plant (PP&E), and the EMtech equity stake. Investing.com shows book value per share of KRW 8,998 at an earlier date. Total debt (short- and long-term split), goodwill and intangibles, and working capital are NPD in the sources reviewed. The liability base of about KRW 0.8bn implies negligible financial debt.
Historical liquidity reference points.
-
H1 2018 report: cash-like assets including short-term financial assets of KRW 44.1bn (cash and equivalents KRW 20.1bn) (Dailypharm, Nov 2018).
-
February 2019: management cited about KRW 50bn of cash-like assets after the EMtech placement (Dealsite, Feb 2019).
Cash flow (FY2025)
Sources: financialfilings.com (CFO); ETF Shopping (FCF). No buyback or treasury-share programme was found (itooza shows no treasury-share ratio). FY2021–FY2024 cash flows are NPD in the sources reviewed.
Commentary on trends, inflections and drivers
Revenue. Revenue has been structurally flat for a decade. It moved between KRW 3.6bn and KRW 8.1bn from FY2016 to FY2025.
-
The FY2021 spike (+95.6% to KRW 8.1bn) was not explained in the sources reviewed.
-
From FY2023 revenue resumed modest single-digit growth: +6.7% in FY2024 and +8.7% in FY2025.
-
Quarterly growth accelerated to +32.5% in Q1 2026 and +16.5% in Q2 2026, before any Allostem contribution.
-
Because Remodulin is described as effectively the sole revenue source, the underlying growth driver through H1 2026 is most likely Remodulin volume. This is an inference, not a disclosure.
Gross margin. Gross margin has compressed steadily, from 71.5% in FY2016 and 47.7% in FY2021 to 35.3% in FY2025. This is consistent with a mix shift away from high-margin own cell therapies and cosmetics towards lower-margin distribution of an imported drug. Allostem supply should be margin-accretive if Anterogen captures a meaningful share of the Japanese insurance price. The transfer-price terms are not disclosed.
Operating losses.
-
Losses peaked in FY2023 (-KRW 5.1bn; -78.1% margin), when Korean and US DFU trials were running concurrently.
-
Losses have since narrowed to -KRW 2.4bn in FY2025 (-32.3% margin). The narrowing reflects trial completions (DFU-302 completed December 2024; the US Wagner 1 trial read out January 2025) and headcount reduction (43 to 29 between FY2022 and FY2024).
-
The Q1 losses (-KRW 1.1bn in both Q1 2025 and Q1 2026) look seasonal or one-off.
Net income versus operating income.
-
Net losses have consistently been smaller than operating losses (FY2025: -KRW 1.4bn versus -KRW 2.4bn), which indicates positive non-operating income.
-
FY2022 is the exception: the net loss (-KRW 6.8bn) exceeded the operating loss (-KRW 4.6bn), suggesting a non-operating charge such as a valuation loss on financial assets or merger-related items.
Balance sheet. The balance sheet is the company's principal financial strength. Equity of KRW 87.45bn against liabilities of about KRW 0.8bn gives roughly 60–80 years of runway at the FY2025 operating cash burn of about KRW 1.0bn. Dilution risk is therefore low unless a large US Phase 3 or capacity expansion is undertaken.
Restatement. The December 2025 amendments to four years of business reports, together with a further amendment to the FY2025 report in May 2026, are a governance and data-quality flag.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Category | Contents | Revenue contribution | Trend | Source |
|---|---|---|---|---|
Imported pharmaceuticals | Remodulin (treprostinil) injection, PAH | Largest; "effectively sole" revenue source | Stable to growing (inferred from total revenue growth) | Medisobizanews, Jun 2026 |
Cell therapy (own) | Cupistem; Queencell (withdrawn); Allostem supply (from Q3 2026) | Negligible through FY2025; Allostem adds from Q3 2026 | Inflecting with Japan launch | Medisobizanews; Medical Daily |
Cosmetics and raw materials | SCM2 line; Therastem line; stem-cell media | NPD | NPD | Investing.com profile |
Services | Stem-cell banking; analytical testing | NPD | NPD | Investing.com profile |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 8.1 | 6.6 | 6.5 | 6.9 | 7.5 |
Cost of sales (KRW Bn) | 4.2 | 4.0 | 3.8 | 4.3 | 4.9 |
Gross profit (KRW Bn) | 3.9 | 2.6 | 2.7 | 2.6 | 2.7 |
Operating income (KRW Bn) | -2.6 | -4.6 | -5.1 | -3.7 | -2.4 |
Net income (KRW Bn) | -0.6 | -6.8 | -2.8 | -2.3 | -1.4 |
EPS basic (KRW) | -59 | -706 | -292 | -236 | -138 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Revenue growth YoY (%) | 95.6 | -18.8 | -1.4 | 6.7 | 8.7 |
Gross margin (%) | 47.7 | 39.7 | 41.0 | 37.9 | 35.3 |
Operating margin (%) | -32.3 | -70.5 | -78.1 | -54.1 | -32.3 |
Net margin (%) | -6.8 | -103.7 | -43.7 | -33.1 | -18.2 |
Income Statement and Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 4.9 | 5.4 | 3.6 | 4.1 | 4.2 |
Gross margin (%) | 71.5 | 60.7 | 46.8 | 40.0 | 42.0 |
Operating income (KRW Bn) | 0.1 | -0.1 | -2.4 | -2.9 | -3.7 |
Net income (KRW Bn) | 0.4 | 0.4 | -1.0 | -4.0 | -4.4 |
EPS basic (KRW) | 50 | 57 | -114 | -470 | -481 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Metric | Q1-24 | Q2-24 | Q3-24 | Q4-24 | Q1-25 | Q2-25 | Q3-25 | Q4-25 | Q1-26 | Q2-26 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 1.5 | 1.7 | 1.9 | 1.8 | 1.6 | 1.9 | 2.0 | 2.0 | 2.1 | 2.2 |
Operating income (KRW Bn) | -1.0 | -0.9 | -0.6 | -1.3 | -1.1 | -0.5 | -0.4 | -0.5 | -1.1 | -0.5 |
Net income (KRW Bn) | -0.6 | -0.5 | -0.2 | -1.0 | -0.7 | -0.1 | -0.1 | -0.5 | -0.9 | -0.1 |
Revenue growth YoY (%) | 0 | 0 | 0 | 0 | 4.6 | 10.4 | 7.4 | 12.0 | 32.5 | 16.5 |
Operating Metrics (headcount) and Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Employees (headcount) | 41 | 43 | 37 | 29 | 32 |
Revenue per employee (KRW Mn) | 200 | 150 | 180 | 240 | 240 |
Operating income per employee (KRW Mn) | -64 | -110 | -140 | -130 | -76 |
Payroll as % of revenue (%) | 17.4 | 24.7 | 20.6 | 15.6 | 14.6 |
Average salary (KRW Mn) | 34.5 | 37.8 | 36.2 | 37.3 | 34.3 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2025 |
|---|---|
Total assets (KRW Bn) | 88.26 |
Total equity (KRW Bn) | 87.45 |
Total liabilities (KRW Bn, derived) | 0.81 |
Cash and cash equivalents (KRW Bn) | 1.6 |
Equity ratio (%, derived) | 99.1 |
Liabilities-to-equity (%, derived) | 0.9 |
Book value per share (KRW, derived at 10.01M shares) | 8,737 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2025 |
|---|---|
Operating cash flow (KRW Bn) | -1.02 |
Free cash flow (KRW Bn) | -1.1 |
Capex (KRW Bn, derived) | 0.1 |
Dividends paid (KRW Bn) | 0 |
Share buybacks (KRW Bn) | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | Note |
|---|---|---|
ROE (%) | -1.6 | ETF Shopping |
ROA (%) | -1.6 | ETF Shopping |
Current ratio | NPD | — |
Debt/equity | ~0 | Liabilities only ~0.9% of equity |
Asset turnover (x, derived) | 0.085 | Revenue 7.54 / assets 88.26 |
Cash conversion cycle | NPD | — |
Geographic Revenue
| Item | Finding | Source |
|---|---|---|
Revenue by segment × geography | NPD | — |
Geographic split (3 years) | NPD; revenue through FY2025 is understood to be predominantly domestic (Korea) | Inference from product mix (Medisobizanews) |
Country-level revenue | NPD | — |
Japan | First export revenue expected from Q3 2026 (1,400 sheets shipped July 2026; about KRW 2.5bn at Japanese insurance price, which is not Anterogen's revenue) | Medical Daily; withnews |
Taiwan | Ishin holds Taiwan rights; no launch disclosed | Biotimes |
US | No commercial revenue; Phase 2 programmes (EB, DFU Wagner 2) | Medisobizanews |
Share Price History
| Date | Price (KRW) | Context | Source |
|---|---|---|---|
3 Jan 2018 | 63,300 | 52-week high at the time | Financial News, Jan 2018 |
2 Aug 2021 | 92,700 | Pre-DFU-301 readout high; market cap about KRW 873bn | Dailypharm, Aug 2021 |
30 Nov 2021 | 54,300 | IR amid insider-sale controversy | Dailypharm, Dec 2021 |
3 Feb 2025 | 17,370 | After the US Phase 2 failure (-21.4%) | Edaily, Feb 2025 |
Early Mar 2026 | 43,000 | MHLW council date announced (+19.78%) | Biotimes |
22 Jun 2026 | 24,400 | 52-week range 20,000–61,800 | itooza |
~20 Jul 2026 | 16,770 | -8.41% on the day | Stockhub |
21 Sep 2026 | 14,540 | — | Asiae ticker |
15 Oct 2026 | 14,020 | 52-week low | ETF Shopping |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
1-month return (%) | -7.9 | ETF Shopping, 15 Oct 2026 |
6-month return (%) | -62.4 | ETF Shopping |
1-year return (%) | -42.4 | ETF Shopping |
3-year and 5-year returns | NPD. From the 2 Aug 2021 high of KRW 92,700 the stock is down about 85% (derived) | Dailypharm; ETF Shopping |
52-week high (KRW) | 58,000 per ETF Shopping; 61,800 per itooza and Stockhub | Discrepancy noted |
52-week low (KRW) | 14,020 per ETF Shopping; 13,500 per Stockhub (July 2026 view) | Discrepancy noted |
Valuation Multiples
| Multiple | Anterogen | Note |
|---|---|---|
Market cap (KRW Bn) | 140.3 | ETF Shopping |
P/E (x) | n/m | Loss-making (EPS -KRW 138) |
P/B (x) | 1.60 | ETF Shopping |
P/S (x, derived) | 18.6 | 140.3 / 7.54 |
EV/Sales | NPD | — |
EV/EBITDA | n/m | Negative EBITDA |
Share Count (thousand)
| Metric | 2016 | 2017 | 2019 | 2025 |
|---|---|---|---|---|
New shares issued (thousand) | 700 | 490 | 210 | 270 |
Analyst Conclusions
Management guidance
-
Quantitative guidance: none.
-
Japanese launch: achieved on 27 July 2026.
-
Expansion to two further countries in Asia and Europe.
-
ANT-301 Phase 2 start within 2026; US IND under review.
-
ANT-501 Phase 1 IND targeted for 2026.
-
US EB Phase 2 continuing.
(Medical Daily, Jul 2026; Medisobizanews, Jun 2026; IR, Mar 2026.)
Consensus
No sell-side consensus exists (Stockhub: 0 reports).
Bull case
-
Allostem economics. At a Japanese insurance price of about JPY 2.96M per set, the 1,400-sheet launch shipment alone was valued at about KRW 2.5bn at insurance prices, roughly one-third of Anterogen's entire FY2025 revenue (KRW 7.5bn). Even a modest share of Japan's 500–1,000 EB patients, through supply revenue plus a royalty of about 9%, could transform the income statement and lift gross margin from its 35.3% FY2025 level.
-
Balance-sheet optionality. Equity of KRW 87.45bn and negligible liabilities give the company the capacity to fund the US EB programme and ANT-301 Phase 2 without near-term dilution. At about 1.6x book, downside is partly anchored by net assets.
-
Label and format advantage. The three-subtype EB label and the off-the-shelf format differentiate Allostem from the DEB-only gene therapy and from autologous grafts. A US Phase 2 success under orphan designation would open a market where the leading DEB product earned USD 389.1M in FY2025.
Bear case
-
Platform credibility. DFU-301 failed in Korea, and the US Wagner 1 Phase 2 showed the active arm numerically worse than control (45.7% vs 60%). DFU-302 data remain unreported more than 21 months after primary completion. The EB success may be indication-specific rather than evidence that the platform works broadly.
-
Commercial execution history. Queencell was withdrawn and Cupistem sales are negligible despite reimbursement. Revenue depends on an imported PAH drug, and gross margin has fallen for a decade. Japanese uptake is in the licensee's hands, and the patient pool is tiny.
-
Governance and overhang. Four years of amended business reports, a history of insider and major-holder selling around catalysts, and EMtech's KRW 16.5bn bond exchangeable into Anterogen shares create disclosure and supply risks. These help explain why the stock fell about 75% from its 52-week high despite the approval.
Catalysts and monitorables (next 12 months)
| Expected timing | Item | Why it matters |
|---|---|---|
| Mid-November 2026 | Q3 2026 report | First period including Allostem shipments; reveals the transfer price and margin |
| Ongoing | Reorder cadence and volume from Ishin | The true demand signal, as opposed to the launch stocking order |
| 2026–2027 | DFU-302 topline disclosure | Fate of the DFU franchise |
| 2,026 | US IND clearance and Phase 2 start for ANT-301 | Second leg of the cell-therapy platform |
| 2,026 | ANT-501 Phase 1 IND | Diversification beyond cell therapy |
| NPD | US EB Phase 2 progress | Path to the largest EB market |
| NPD | Taiwan or other filings by Ishin; additional country deals | Geographic expansion |
| Ongoing | EMtech EB exchange activity and large-holding filings | Share-supply overhang |
| March 2027 | FY2026 business report | Absence of further amendments would signal improved disclosure quality |
Analyst verdict
Anterogen has reached the point every cell-therapy developer aims for: a regulator-approved, reimbursed product in a demanding market, manufactured in its own accredited plants and shipped commercially. The Japanese approval of Allostem in April 2026 validates the off-the-shelf allogeneic ASC sheet as a product. It is a genuine first for a Korean stem-cell developer.
Yet the market has treated the approval as the end of a story rather than the start of one. The share price fell from a 52-week high of KRW 58,000–61,800 to KRW 14,020 within roughly six months. At about 1.6x book and roughly 19x trailing sales, the market is pricing Allostem as a niche orphan product with uncertain economics and is assigning little value to the rest of the pipeline.
That scepticism is evidence-based. The company's own record shows:
-
Two domestic products that never scaled.
-
Revenue that has been flat around KRW 4–8bn for a decade and depends on an imported drug.
-
Two failed DFU efficacy readouts.
-
Repeated governance blemishes, including restated filings.
Against this, the balance sheet is exceptionally clean, the burn is small, and the Japanese price point is high enough that even dozens of treated patients would be material to a company of this size.
Verdict. Anterogen is a high-uncertainty, catalyst-dependent special situation, not a compounding growth franchise. The key variable over the next 12 months is the Q3 and Q4 2026 revenue lines: the first transparent read of Allostem's transfer price, gross margin and reorder frequency. Positive revisions to Japanese uptake, a disclosed and favourable DFU-302 outcome, or US progress in EB or ANT-301 could justify a re-rating towards prior levels. Absent those, the stock is likely to trade near net asset value while the market waits for proof that Anterogen can convert regulatory success into durable commercial revenue, something its history has not yet demonstrated.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Shareholding | Source |
|---|---|---|---|---|
Lee Sung-gu (이성구) | Co-CEO, representative director; founder; largest shareholder | Founded Anterogen in 2000 while a Bukwang Pharmaceutical executive; Bukwang CEO 2004–2013 while also leading Anterogen. Education and age NPD | 12.16% | DART FY2025; Dealsite, Jan 2019 |
Kim Mi-hyung (김미형) | Co-CEO, representative director | Co-CEO since Mar 2018; public face of Japan approval and commercialisation communications (2023–2026). Education and age NPD | 0.87% | DART FY2025; Jobplanet; Hankyung |
Kim In-ok (김인옥) | Executive; Head of Research Institute | Head of research institute (cited 2018) | 0.37% | DART FY2025; Dailypharm, Nov 2018 |
Lee Tae-hee (이태희) | Executive | NPD | 0.11% | DART FY2025 |
Ryu Hong-gi (류홍기) | Executive | NPD | 0.02% | DART FY2025 |
Workforce Metrics
| Metric | FY2025 | Source |
|---|---|---|
Average pay per director/auditor (KRW Mn) | 110 | DART FY2025 (6 persons) |
Ratio to average employee pay (x) | 3.3 | ETF Shopping (derived) |
Individuals paid ≥ KRW 500M | None disclosed | DART individual-disclosure threshold |
Major Shareholders
| Holder | Relationship | Stake (%) | Source |
|---|---|---|---|
Lee Sung-gu | Largest shareholder | 12.16 | DART FY2025 |
Jang Wan-soon | Relative | 0.90 | DART FY2025 |
Kim Mi-hyung | Executive | 0.87 | DART FY2025 |
Kim In-ok | Executive | 0.37 | DART FY2025 |
Lee Tae-hee | Executive | 0.11 | DART FY2025 |
Lee Hye-mi | Relative | 0.10 | DART FY2025 |
Lee Young-jae | Relative | 0.04 | DART FY2025 |
Kwon Mi-sun | Relative | 0.03 | DART FY2025 |
Ryu Hong-gi | Executive | 0.02 | DART FY2025 |
Largest shareholder + related parties | — | 14.60 | DART FY2025 |
EMtech Co., Ltd. | 5%+ holder (report dated 21 Apr 2026) | 7.25 | Large-holding report |
Minority shareholders (12,965 holders) | — | 71.28 | DART FY2025 |
Metric | FY2021 | FY2022 | FY2023 |
Largest shareholder + related parties stake (%) | 14.34 | 15.03 | 15.03 |
Competitive Landscape
Competitors by Segment
| Area | Competitor | Product / approach | Relative positioning | Source / note |
|---|---|---|---|---|
EB (Japan and global) | Krystal Biotech (US) | Vyjuvek (B-VEC), topical redosable HSV-1 gene therapy for DEB; approved in the US (2023) and in Japan and Europe (2025) | Incumbent DEB leader; FY2025 Vyjuvek net revenue USD 389.1M; 94% gross margin. DEB only, whereas Allostem's Japanese label also covers JEB and severe EBS | Krystal 8-K, Feb 2026 |
EB (Japan) | Japan Tissue Engineering (J-TEC) | Autologous cultured epidermis for EB | Autologous (needs a patient biopsy and culture); Allostem is off-the-shelf | Daily Invest (Kiwoom commentary) |
EB (global) | Abeona Therapeutics (US) | Autologous gene-corrected keratinocyte sheets (pz-cel) for RDEB | Surgical grafting; US-focused | — |
EB (global) | Chiesi | Topical birch-bark extract gel for EB wounds | Supportive wound therapy | — |
Crohn's fistula | Takeda | Darvadstrocel (allogeneic ASC) | Direct mechanistic analogue to Cupistem and ALLO-ASC-CD | — |
Korean cell therapy | Medipost | Cartistem (umbilical-cord MSC, cartilage) | Larger Korean MSC player; competes with ANT-301 in knee OA | Biospectator, 2014 |
Korean cell therapy | Pharmicell | Cellgram-AMI (bone-marrow MSC, acute MI) | Early Korean approval peer | PMC review; Biospectator |
Korean cell therapy | CHA Biotech | Cell-therapy platforms | Listed on THE VC as a similar company | THE VC |
Korean cell therapy | Hurim Biocell | Cell therapy | Listed on THE VC as a similar company | THE VC |
Korean cell therapy | Corestem, Tego Science, Kangstem Biotech, S.Biomedics | Various MSC and tissue products | Domestic peers for capital and talent | General industry knowledge; financials NV |
DFU / wound care | Advanced wound-care incumbents (bioengineered skin substitutes, amniotic membranes, growth-factor products) | Established standard-of-care adjuncts | Anterogen's DFU programme has failed twice; no competitive position yet | IR (amnion comparison study, 2021) |
Herpes zoster | Acyclovir, valacyclovir and famciclovir (generic); recombinant zoster vaccines for prevention | Standard-of-care antivirals and vaccines | ANT-501 is preclinical | Company IR, 2023/2026 |
Peer Comparison FY2025
| Metric | Anterogen (FY2025) | Krystal Biotech (FY2025) | Medipost | Takeda (darvadstrocel) |
|---|---|---|---|---|
Revenue (local currency, M) | 7,540 | 389.1 | NV | NV |
Revenue currency | KRW | USD | — | — |
Revenue growth (%) | 8.7 | NV | NV | NV |
Gross margin (%) | 35.3 | 94 | NV | NV |
Operating margin (%) | -32.3 | NV | NV | NV |
R&D intensity (%) | NPD | NV | NV | NV |



